临床肿瘤学杂志

• 综述与讲座 • 上一篇    下一篇

奥沙利铂治疗肝细胞癌耐药的相关机制研究进展

郑美玲,华海清

  

  1. 210002 南京 南京中医药大学附属八一医院全军肿瘤中心
  • 收稿日期:2017-01-22 修回日期:2017-02-21 出版日期:2017-04-30 发布日期:2017-04-30
  • 通讯作者: 华海清

Progress of resistance mechanism of oxaliplatin on hepatocellular carcinoma

ZHENG Meiling,HUA Haiqing   

  1. Cancer Center of PLA,81 Hospital Affiliated to Nangjing University of Chinese Medicine,Nangjing 210002,China
  • Received:2017-01-22 Revised:2017-02-21 Online:2017-04-30 Published:2017-04-30
  • Contact: HUA Haiqing

摘要:

奥沙利铂在我国已被批准用于晚期肝细胞癌(HCC)的治疗,以奥沙利铂为基础的FOLFOX 4方案已成为晚期HCC的标准治疗之一,显著延长了患者的生存期,展现出安全有效、耐受性良好等特点。尽管如此,奥沙利铂治疗HCC的临床疗效仍十分有限,其治疗失败与HCC产生耐药密切相关。本文就奥沙利铂治疗HCC的耐药机制研究进展作一综述,希望能帮助临床和科研工作者了解最新动态,并为他们的工作拓宽思路。

Abstract:

Oxaliplatin has been approved for the treatment of advanced hepatocellular carcinoma(HCC)in China. FOLFOX4 regimen based on oxaliplatin has become one of the standard treatments for advanced HCC,which can significantly prolong the survival of patients with HCC,and also show good safety and tolerance. However,the clinical efficacy of oxaliplatin on HCC is very limited. The treatment failure is closely related to the resistance of HCC. This article reviews the progress about current researches on the resistance mechanism of oxaliplatin in the treatment of HCC,arming to help clinical and scientific researchers to understand the latest development,and to broaden their thinking in future work.

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!